摘要
目的研究恩替卡韦(entekavir,ETV)治疗慢性乙型肝炎患者过程中Th17细胞的变化。方法在应用ETV治疗的不同时间点抽取HBV感染患者及健康对照者静脉血,分离血清及外周血单核细胞(PMBC),检测血清中乙型肝炎病毒表面标志物(HBV-M)、乙型肝炎病毒核酸定量(HBVDNA)、丙氨酸转移酶(ALT)以及外周血中的Th17细胞的频数。结果应用ETV治疗后患者ALT及HBVDNA从4周开始出现明显下降,IL-17+及IL-17+IFN-γ-T细胞的频数在第4周时明显升高[IL-17+(6.32±2.26)%,IL-17+IFN-γ-T(4.68±1.73)%],其后逐渐下降至24周,在48周时接近于基线点,在所有时间点均高于健康对照(P<0.05)。IL-17+IFN-γ+T细胞的频数第4周时明显升高,在36周时达到峰值[IL-17+IFN-γ+T(1.92±0.97)%],在48周时明显下降,但在所有时间点明显高于健康对照(P<0.05)。结论 ETV在有效抑制病毒复制的同时,能够降低体内Th17细胞的频数,意味着体内炎症反应的减轻,同时也可能削弱机体清除病毒的能力。
Objective To investigate the profiles of Th17 cells in chronically HBV-infected patients with enticarvir （ETV） treatment. Methods Serum and peripheral blood monouclear cells （PBMCs） were obtained from 9 enrolled CHB patients who admitted in our center in December 2008 and 9 matched health controls. The patients were administered 0.5 mg ETV, once per day for 48 weeks. Their ALT, HBV DNA, HBV markers as well as the frequency of Th17 cells were measured and monitored in 4, 12, 24, 36 and 48 weeks after the treatment. Results There was a significant decrease in ALT and HBV DNA levels in patients after 4 weeks’ ETV treatment, but the percentage of peripheral IL-17＋ and IL-17＋IFN-γ-T cells were significantly increased from the 4th week [（6.32±2.26）% and （4.68±1.73）% respectively] and then gradually decreased later till 24 weeks, even almost closed to the baselines at the end of 48 weeks’ treatment, but they still higher than the counterparts in healthy controls at any time point. The percentage of peripheral IL-17＋IFN-γ＋ T cells was increased significantly at the 36th week [（1.92±0.97）%], and then decreased significantly after 48 weeks’ treatment, though much higher than that of healthy controls at any time point. Conclusion ETV efficiently suppresses HBV replication, which may be correlated with the decrease of Th17 cells and thus might attenuate hepatic inflammation in the disease.
出处
《第三军医大学学报》
CAS
CSCD
北大核心
2010年第22期2417-2419,共3页
Journal of Third Military Medical University
